H.C. Wainwright Initiates Coverage on SINTX Technologies with Buy Rating, Highlighting Silicon Nitride Platform Opportunity
April 23, 2026
Independent analyst coverage underscores SINTX’s transition to a commercial-stage biomaterials company, citing its silicon nitride technology, recent FDA clearance and first human implant, and a scalable platform strategy across orthopedics and adjacent healthcare markets.
Recent News
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test
- Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology
